Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment is a phase 3, randomised interventional study registered as NCT06642844 by University Hospital, Tours, with a registry enrolment figure of 244 participants, started 2025-03-04 and due to reach its primary completion in 2028-03-04. Interventions recorded: Avastin, 25 Mg/mL Intravenous Solution. Conditions listed: Unresectable Metastatic Colorectal Cancer. Primary outcome: The primary endpoint is progression-free survival (PFS). Colorectal eligibility wording from the registry: "* Histologically proven metastatic colorectal adenocarcinoma (on primary tumor and/or metastases) inoperable, well documented, i". Sites: France. No results are recorded here; the registry entry is the source.